440 related articles for article (PubMed ID: 24690241)
1. GPCR-targeting nanobodies: attractive research tools, diagnostics, and therapeutics.
Mujić-Delić A; de Wit RH; Verkaar F; Smit MJ
Trends Pharmacol Sci; 2014 May; 35(5):247-55. PubMed ID: 24690241
[TBL] [Abstract][Full Text] [Related]
2. Nanobodies: New avenues for imaging, stabilizing and modulating GPCRs.
De Groof TWM; Bobkov V; Heukers R; Smit MJ
Mol Cell Endocrinol; 2019 Mar; 484():15-24. PubMed ID: 30690070
[TBL] [Abstract][Full Text] [Related]
3. Nanobodies detecting and modulating GPCRs outside in and inside out.
Heukers R; De Groof TWM; Smit MJ
Curr Opin Cell Biol; 2019 Apr; 57():115-122. PubMed ID: 30849632
[TBL] [Abstract][Full Text] [Related]
4. Nanobodies and their Use in GPCR Drug Discovery.
Cromie KD; Van Heeke G; Boutton C
Curr Top Med Chem; 2015; 15(24):2543-57. PubMed ID: 26126902
[TBL] [Abstract][Full Text] [Related]
5. Antibodies Targeting Chemokine Receptors CXCR4 and ACKR3.
Bobkov V; Arimont M; Zarca A; De Groof TWM; van der Woning B; de Haard H; Smit MJ
Mol Pharmacol; 2019 Dec; 96(6):753-764. PubMed ID: 31481460
[TBL] [Abstract][Full Text] [Related]
6. Yeast surface display platform for rapid discovery of conformationally selective nanobodies.
McMahon C; Baier AS; Pascolutti R; Wegrecki M; Zheng S; Ong JX; Erlandson SC; Hilger D; Rasmussen SGF; Ring AM; Manglik A; Kruse AC
Nat Struct Mol Biol; 2018 Mar; 25(3):289-296. PubMed ID: 29434346
[TBL] [Abstract][Full Text] [Related]
7. Nanobodies as Probes and Modulators of Cardiovascular G Protein-Coupled Receptors.
Wingler LM; Feld AP
J Cardiovasc Pharmacol; 2022 Sep; 80(3):342-353. PubMed ID: 34840268
[TBL] [Abstract][Full Text] [Related]
8. Antibodies targeting G protein-coupled receptors: Recent advances and therapeutic challenges.
Ayoub MA; Crépieux P; Koglin M; Parmentier M; Pin JP; Poupon A; Reiter E; Smit M; Steyaert J; Watier H; Wilkinson T
MAbs; 2017 Jul; 9(5):735-741. PubMed ID: 28475474
[TBL] [Abstract][Full Text] [Related]
9. Structural basis for selectivity and antagonism in extracellular GPCR-nanobodies.
Schlimgen RR; Peterson FC; Heukers R; Smit MJ; McCorvy JD; Volkman BF
Nat Commun; 2024 May; 15(1):4611. PubMed ID: 38816420
[TBL] [Abstract][Full Text] [Related]
10. Introduction to heavy chain antibodies and derived Nanobodies.
Vincke C; Muyldermans S
Methods Mol Biol; 2012; 911():15-26. PubMed ID: 22886243
[TBL] [Abstract][Full Text] [Related]
11. High yield purification of nanobodies from the periplasm of E. coli as fusions with the maltose binding protein.
Salema V; Fernández LÁ
Protein Expr Purif; 2013 Sep; 91(1):42-8. PubMed ID: 23856605
[TBL] [Abstract][Full Text] [Related]
12. Identification of Useful Nanobodies by Phage Display of Immune Single Domain Libraries Derived from Camelid Heavy Chain Antibodies.
Romao E; Morales-Yanez F; Hu Y; Crauwels M; De Pauw P; Hassanzadeh GG; Devoogdt N; Ackaert C; Vincke C; Muyldermans S
Curr Pharm Des; 2016; 22(43):6500-6518. PubMed ID: 27669966
[TBL] [Abstract][Full Text] [Related]
13. Nanobody-based products as research and diagnostic tools.
De Meyer T; Muyldermans S; Depicker A
Trends Biotechnol; 2014 May; 32(5):263-70. PubMed ID: 24698358
[TBL] [Abstract][Full Text] [Related]
14. Nanobodies: natural single-domain antibodies.
Muyldermans S
Annu Rev Biochem; 2013; 82():775-97. PubMed ID: 23495938
[TBL] [Abstract][Full Text] [Related]
15. Nanobodies®: proficient tools in diagnostics.
Huang L; Muyldermans S; Saerens D
Expert Rev Mol Diagn; 2010 Sep; 10(6):777-85. PubMed ID: 20843201
[TBL] [Abstract][Full Text] [Related]
16. Nanobodies: From Serendipitous Discovery of Heavy Chain-Only Antibodies in Camelids to a Wide Range of Useful Applications.
Ji F; Ren J; Vincke C; Jia L; Muyldermans S
Methods Mol Biol; 2022; 2446():3-17. PubMed ID: 35157266
[TBL] [Abstract][Full Text] [Related]
17. Nanobodies and their potential applications.
Hassanzadeh-Ghassabeh G; Devoogdt N; De Pauw P; Vincke C; Muyldermans S
Nanomedicine (Lond); 2013 Jun; 8(6):1013-26. PubMed ID: 23730699
[TBL] [Abstract][Full Text] [Related]
18. Nanobodies: The Future of Antibody-Based Immune Therapeutics.
Bathula NV; Bommadevara H; Hayes JM
Cancer Biother Radiopharm; 2021 Mar; 36(2):109-122. PubMed ID: 32936001
[TBL] [Abstract][Full Text] [Related]
19. Nanobodies to Study G Protein-Coupled Receptor Structure and Function.
Manglik A; Kobilka BK; Steyaert J
Annu Rev Pharmacol Toxicol; 2017 Jan; 57():19-37. PubMed ID: 27959623
[TBL] [Abstract][Full Text] [Related]
20. The 7 TM G-protein-coupled receptor target family.
Jacoby E; Bouhelal R; Gerspacher M; Seuwen K
ChemMedChem; 2006 Aug; 1(8):761-82. PubMed ID: 16902930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
